All News

The 2 phase 3 trials met all primary and secondary endpoints, showing statistically significant reduction in symptoms and sleep disturbance and improvement in quality of life.

In the phase 1b trial, treatment with once-weekly subcutaneous CT-388 led to a statistically significant mean placebo-adjusted weight loss of nearly 20%.

Your daily dose of the clinical news you may have missed.

Sipavibart met both dual primary endpoints in the SUPERNOVA phase 3 trial.

Safety and HbA1c reduction with efsitora alfa dosed once weekly was comparable to both daily insulin degludec and daily insulin glargine, announced Lilly.

New research shows that menstrual irregularity is associated with a higher prevalence of cardiometabolic conditions in women, even in the absence of PCOS.

Get a quick overview of recommendations for preventive health services and screenings focused on the unique needs of women across the lifespan.

Your daily dose of the clinical news you may have missed.

Find details on a novel web tool found to help patients determine their eligibility for OTC statin use, FDA clearance of the first AI-based algorithm to detect HF during routine exams, and more.

Your daily dose of the clinical news you may have missed.

While Moderna expects mRNA-1345 to be approved later this month, the company cites FDA administrative constraints as reason for delay.

Your daily dose of the clinical news you may have missed.

Patient is in his forties; pain has been waxing, waning, worsening for 2 weeks. He has no other significant medical history. Do lab results hold clues? What's your Dx?

Women referred from obstetrics to primary care postpartum via a pilot program were more likely to attend a PCP visit than nonreferred women.

There have been 224 reported injuries as of April 15, 2024, the CDC said, but no reports of death related to the app intermittently crashing and rebooting.

A new analysis found triple therapy for COPD, particularly B/G/F, more cost-effective vs dual therapy in terms of exacerbations and quality-adjusted life years.

The company will present new data on effects of tezepelumab in COPD and of inhaled triple therapy Breztri on cardiopulmonary outcomes in COPD.